However, treatment significantly reduced activated Tregs in the tumor microenvironment: Foxp3+CTLA4+ CD4+ Tregs were reduced in all patients, from 11.8% to 2.9%, p = 0.0067 (Fig. 4b). This evidence concerns the gene FOXP3 and neoplasm.